Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bezafibrate and Obeticholic Acid in Primary Biliary Cholangitis
NCT05239468Phase 2Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- Mar 2022
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of bezafibrate and obeticholic acid in primary biliary cholangitis (PBC) (5 arms), sponsored by Intercept Pharmaceuticals. Primary endpoint: Change From Baseline in Alkaline Phosphatase at 12 weeks. Started Mar 2022; status: completed.
02
Drugs
bezafibrateobeticholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT05239468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05239468.